Barclays’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $709K | Buy |
44,341
+12,546
| +39% | +$201K | ﹤0.01% | 2851 |
|
|
2025
Q1 | $484K | Sell |
31,795
-26,771
| -46% | -$408K | ﹤0.01% | 2866 |
|
|
2024
Q4 | $1.19M | Buy |
58,566
+26,733
| +84% | +$542K | ﹤0.01% | 2533 |
|
|
2024
Q3 | $819K | Buy |
31,833
+23,536
| +284% | +$606K | ﹤0.01% | 2739 |
|
|
2024
Q2 | $107K | Buy |
8,297
+5,055
| +156% | +$65.2K | ﹤0.01% | 3343 |
|
|
2024
Q1 | $74K | Buy |
3,242
+2,538
| +361% | +$57.9K | ﹤0.01% | 3739 |
|
|
2023
Q4 | $18K | Sell |
704
-1,066
| -60% | -$27.3K | ﹤0.01% | 3984 |
|
|
2023
Q3 | $50K | Buy |
1,770
+1,065
| +151% | +$30.1K | ﹤0.01% | 3599 |
|
|
2023
Q2 | $21K | Sell |
705
-1,171
| -62% | -$34.9K | ﹤0.01% | 3968 |
|
|
2023
Q1 | $35K | Buy |
1,876
+552
| +42% | +$10.3K | ﹤0.01% | 3870 |
|
|
2022
Q4 | $13K | Buy |
1,324
+521
| +65% | +$5.12K | ﹤0.01% | 4099 |
|
|
2022
Q3 | $22K | Sell |
803
-14
| -2% | -$384 | ﹤0.01% | 3908 |
|
|
2022
Q2 | $37K | Sell |
817
-341
| -29% | -$15.4K | ﹤0.01% | 3855 |
|
|
2022
Q1 | $114K | Buy |
+1,158
| New | +$114K | ﹤0.01% | 3608 |
|